| Trial ID: | L6889 |
| Source ID: | NCT00747383
|
| Associated Drug: |
Glimepiride
|
| Title: |
How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.
|
| Acronym: |
MSD-GLP1
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Glimepiride|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Comparison of GLP-1 response at baseline and after 3 months treatment of both groups., 2 years |
|
| Sponsor/Collaborators: |
Sponsor: The Royal Bournemouth Hospital | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
74
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-09
|
| Completion Date: |
2010-09
|
| Results First Posted: |
|
| Last Update Posted: |
2012-12-05
|
| Locations: |
Royal Bournemouth Hospital, Bournemouth, Dorset, BH7 7DW, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00747383
|
